The Trump Administration expects that allowing Medicare Advantage plans to use step therapy to manage Part B drugs could save 15% to 20% in annual costs on average, according to Dan Best, senior advisor to HHS Secretary Alex Azar for drug pricing reform.
His estimate is based on the savings typically generated through use of step therapy by commercial plans for similar categories of physician-administered drugs. Best offered the projection during an Aug....